Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
103.24
-1.59 (-1.52%)
At close: Feb 25, 2026, 4:00 PM EST
92.94
-10.30 (-9.98%)
After-hours: Feb 25, 2026, 5:13 PM EST
Revolution Medicines Stock Forecast
Stock Price Forecast
The 16 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $102.63, which forecasts a -0.59% decrease in the stock price over the next year. The lowest target is $64 and the highest is $170.
Price Target: $102.63 (-0.59%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 9 | 9 | 8 | 8 |
| Buy | 7 | 6 | 9 | 9 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 18 | 18 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $92 → $122 | Buy | Maintains | $92 → $122 | +18.17% | Feb 2, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $75 → $150 | Buy | Maintains | $75 → $150 | +45.29% | Jan 27, 2026 |
| Stifel | Stifel | Strong Buy Maintains $85 → $170 | Strong Buy | Maintains | $85 → $170 | +64.66% | Jan 22, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $77 → $140 | Buy | Maintains | $77 → $140 | +35.61% | Jan 21, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $92 → $160 | Strong Buy | Maintains | $92 → $160 | +54.98% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
4.50M
Revenue Next Year
38.64M
from 4.50M
Increased by 758.37%
EPS This Year
-5.71
from -3.58
EPS Next Year
-6.76
from -5.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 43.8M | 200.3M | ||||
| Avg | 4.5M | 38.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 4,350.0% | ||||
| Avg | - | 758.4% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.19 | -5.30 | ||||
| Avg | -5.71 | -6.76 | ||||
| Low | -5.64 | -7.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.